Tags

Type your tag names separated by a space and hit enter

Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients.
Hypertens Res. 2001 Nov; 24(6):641-6.HR

Abstract

The object of this study is to evaluate the long-term effects of olmesartan on hypertension and the renin-angiotensin-aldosterone system in hypertensive patients. This study evaluated 26 hypertensive male and female outpatients, 38-69 years of age, with a systolic blood pressure > or = 160 mmHg and/or a diastolic blood pressure > or = 95 mmHg. Oral doses of 5 to 40 mg olmesartan were administered once daily. Blood pressure and renin-angiotensin-aldosterone parameters (plasma renin activity and plasma angiotensin I, II, and aldosterone concentrations) were evaluated at 12-16 weeks, 6 months, and 1 year after the start of olmesartan administration. Systolic and diastolic blood pressures were significantly decreased following the administration of olmesartan. The observed decreases in systolic and diastolic blood pressures after 1 year of treatment were 28.8+/-2.1 mmHg and 15.8+/-1.3 mmHg, respectively. No change was observed in the pulse rate. The plasma renin activity increased significantly from a baseline premedication mean of 1.26+/-0.31 ng/ml/h to a mean of 2.58+/-0.74 ng/ml/h and 2.87+/-0.72 ng/ml/h after 6 months and 1 year of treatment, respectively. Angiotensin II levels decreased significantly from a baseline of 20.4+/-3.2 pg/ml to a mean of 8.6+/-2.1 pg/ml and 6.8+/-1.8 pg/ml after 6 months and 1 year of treatment, respectively. The plasma aldosterone level also decreased significantly after 6 months of treatment. In hypertensive patients, the long-term administration of olmesartan, a novel AT1 receptor antagonist, decreased both blood pressure and plasma angiotensin II levels.

Authors+Show Affiliations

Department of Internal Medicine, Cardiovascular Hospital of Central Japan, Seta-gun, Gunma. ichikawa@ccj.or.jpNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

11768722

Citation

Ichikawa, S, and Y Takayama. "Long-term Effects of Olmesartan, an Ang II Receptor Antagonist, On Blood Pressure and the Renin-angiotensin-aldosterone System in Hypertensive Patients." Hypertension Research : Official Journal of the Japanese Society of Hypertension, vol. 24, no. 6, 2001, pp. 641-6.
Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res. 2001;24(6):641-6.
Ichikawa, S., & Takayama, Y. (2001). Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension Research : Official Journal of the Japanese Society of Hypertension, 24(6), 641-6.
Ichikawa S, Takayama Y. Long-term Effects of Olmesartan, an Ang II Receptor Antagonist, On Blood Pressure and the Renin-angiotensin-aldosterone System in Hypertensive Patients. Hypertens Res. 2001;24(6):641-6. PubMed PMID: 11768722.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. AU - Ichikawa,S, AU - Takayama,Y, PY - 2002/1/5/pubmed PY - 2002/5/23/medline PY - 2002/1/5/entrez SP - 641 EP - 6 JF - Hypertension research : official journal of the Japanese Society of Hypertension JO - Hypertens Res VL - 24 IS - 6 N2 - The object of this study is to evaluate the long-term effects of olmesartan on hypertension and the renin-angiotensin-aldosterone system in hypertensive patients. This study evaluated 26 hypertensive male and female outpatients, 38-69 years of age, with a systolic blood pressure > or = 160 mmHg and/or a diastolic blood pressure > or = 95 mmHg. Oral doses of 5 to 40 mg olmesartan were administered once daily. Blood pressure and renin-angiotensin-aldosterone parameters (plasma renin activity and plasma angiotensin I, II, and aldosterone concentrations) were evaluated at 12-16 weeks, 6 months, and 1 year after the start of olmesartan administration. Systolic and diastolic blood pressures were significantly decreased following the administration of olmesartan. The observed decreases in systolic and diastolic blood pressures after 1 year of treatment were 28.8+/-2.1 mmHg and 15.8+/-1.3 mmHg, respectively. No change was observed in the pulse rate. The plasma renin activity increased significantly from a baseline premedication mean of 1.26+/-0.31 ng/ml/h to a mean of 2.58+/-0.74 ng/ml/h and 2.87+/-0.72 ng/ml/h after 6 months and 1 year of treatment, respectively. Angiotensin II levels decreased significantly from a baseline of 20.4+/-3.2 pg/ml to a mean of 8.6+/-2.1 pg/ml and 6.8+/-1.8 pg/ml after 6 months and 1 year of treatment, respectively. The plasma aldosterone level also decreased significantly after 6 months of treatment. In hypertensive patients, the long-term administration of olmesartan, a novel AT1 receptor antagonist, decreased both blood pressure and plasma angiotensin II levels. SN - 0916-9636 UR - https://www.unboundmedicine.com/medline/citation/11768722/Long_term_effects_of_olmesartan_an_Ang_II_receptor_antagonist_on_blood_pressure_and_the_renin_angiotensin_aldosterone_system_in_hypertensive_patients_ L2 - http://joi.jlc.jst.go.jp/JST.JSTAGE/hypres/24.641?from=PubMed DB - PRIME DP - Unbound Medicine ER -